Skip to main content
Normal View

Medicinal Products Reimbursement

Dáil Éireann Debate, Tuesday - 19 November 2019

Tuesday, 19 November 2019

Questions (409)

Willie O'Dea


409. Deputy Willie O'Dea asked the Minister for Health further to Parliamentary Question No. 279 of 22 October 2019, if osimertinib for adult patients with locally advanced or metastatic EGFRT790M mutation-positive non-small cell lung cancer will be made available from 1 January 2020; if the HSE senior leadership team has discussed the reimbursement of the drug for adult patients with same subsequent to its decision of 9 July 2019 that it was minded to approve the drug; and if he will make a statement on the matter. [47536/19]

View answer

Written answers (Question to Health)

The Health Service Executive has operational responsibility for medicines expenditure, thus the matter has been referred to the HSE for their attention and direct reply to the Deputy.